Aim: Recent evidence shows that cultured mycelium Cordyceps sinensis (CMCS) effectively protects against liver fibrosis in mice. Here, we investigated whether the anti-fibrotic action of CMCS was related to its regulation of the activity of hepatic natural killer (NK) cells in CCl 4 -treated mice. Methods: C57BL/6 mice were injected with 10% CCl 4 (2 mL/kg, ip) 3 times per week for 4 weeks, and received CMCS (120 mg·kg -1 ·d -1 , ig) during this period. In another part of experiments, the mice were also injected with an NK cell-deleting antibody ASGM-1 (20 μg, ip) 5 times in the first 3 weeks. After the mice were sacrificed, serum liver function, and liver inflammation, hydroxyproline content and collagen deposition were assessed. The numbers of hepatic NK cells and expression of NKG2D (activation receptor of NK cells) on isolated liver lymphocytes were analyzed using flow cytometry. Desmin expression and cell apoptosis in liver tissues were studied using desmin staining and TUNEL assay, respectively. The levels of α-SMA, TGF-β, RAE-1δ and RAE-1ε in liver tissues were determined by RTqPCR. Results: in CCl 4 -treated mice, CMCS administration significantly improved liver function, attenuated liver inflammation and fibrosis, and increased the numbers of hepatic NK cells and expression level of NKG2D on hepatic NK cells. Furthermore, CMCS administration significantly decreased desmin expression in liver tissues, and increased TUNEL staining adjacent to hepatic stellate cells. Injection with NK cell-deleting ASGM-1 not only diminished the numbers of hepatic NK cells, but also greatly accelerated liver inflammation and fibrosis in CCl 4 -treated mice. In CCl 4 -treated mice with NK cell depletion, CMCS administration decelerated the rate of liver fibrosis development, and mildly upregulated the numbers of hepatic NK cells but without changing NKG2D expression. Conclusion: CMCS alleviates CCl 4 -induced liver inflammation and fibrosis via promoting activation of hepatic NK cells. CMCS partially reverses ASGM-1-induced depletion of hepatic NK cells.
Introduction
Liver fibrosis is a progressive pathological process in which wound-healing myofibroblasts of the liver respond to injury by promoting the replacement of normal hepatic tissue with a scar-like matrix composed of cross-linked collagen [1] . Hepatic stellate cells (HSCs) are quiescent in a healthy liver and play a central role in the storage of vitamin A. When injury occurs, HSCs become activated and transdifferentiate into myofibroblasts [2] , which express α-smooth muscle actin (α-SMA). Accumulated evidence suggests that the activation of HSCs is a key step in the development of liver fibrosis, and hepatic fibrosis was once considered irreversible [3] . By contrast, advanced liver fibrosis is potentially reversible via the induction of HSC apoptosis. Consequently, there is now considerable interest in promoting HSC apoptosis and in the discovery of drugs that will induce HSC apoptosis in a selective manner.
Natural killer (NK) cells are lymphocytes of the innate immune system and are present among total blood lymphocytes and in various tissues, including the bone marrow, . Accumulating evidence suggests that the function of NK cells is strongly influenced by the tissue microenvironment [5] . The decision to kill a target cell depends on the net balance of signals delivered by inhibitory and activating receptor molecules that are expressed on the NK cell surface. The inhibitory receptors, which subsequently inactivate NK cell functions, include killer Ig-like receptors, Ly-49A and CD94/NKG2 receptors that recognize MHC class I molecules (inhibitory ligands). The stimulatory receptors, which are collectively referred to as natural cytotoxicity receptors, include NKp46, NKp30 and NKp44, NKG2D and DNAX accessory molecule-1 (CD226) [6] [7] [8] . Among these, NKG2D is the most well-defined receptor. NKG2D binds to its ligands (eg, RAE-1δ and RAE-1ε on HSCs in C57BL/6 mice) expressed on target cells and subsequently promotes NK cell activation [8] . In a healthy liver, NK cells have a cytotoxic role against stressed, transformed or infected cells by integrating several signals that are transduced by various activating and inhibitory surface receptors without prior sensitization [6] , as compared with peripheral NK cells [9] . Healthy liver NK cells play critical roles in controlling liver fibrogenesis by recognizing and killing activated HSCs [10, 11] , as demonstrated in both animal models and patients [12] [13] [14] . NK cells have been shown to selectively recognize and kill early activated HSCs rather than quiescent or fully activated HSCs (myofibroblasts) [15] . In addition, the anti-fibrogenic effects of NK cells have been shown to be suppressed during advanced liver injury due to the increased production of transforming growth factor-beta (TGF-β) in intermediately activated HSCs [16] . Thus, downregulation of the activities of NK cells may contribute to the progression of liver fibrosis.
The cultured mycelium Cordyceps sinensis (CMCS), a Chinese herbal medicine, is capable of inhibiting inflammation and regulating the immune system [17] . The number and cytotoxicity of NK cells have been reported to increase significantly in response to C. sinensis both in vitro and in vivo [18] [19] [20] . Our previous study revealed that CMCS could inhibit liver fibrosis and had no nocuous effects on normal tissues [21, 22] . Nevertheless, the mechanism by which CMCS protects against liver fibrosis and whether an immunological response may be involved in this process remain unclear. Because CMCS can rescue the functions of weakened NK cells in different types of diseases, the aim of this study was to explore whether the antifibrotic effect of CMCS is related to its regulation of NK cell activities.
Materials and methods

Reagents
Analytical reagent grade carbon tetrachloride (CCl 4 ) was obtained from Sinopharm Group Co, Ltd (Shanghai, China). All other chemicals and solvents were of analytical grade.
Drug preparation CMCS in powder form was purchased from Shanghai Sundise Chinese Medicine Technology Development Co, Ltd (Shanghai, China). The extraction process applied for CMCS and the determination and quantitation of active compounds in CMCS by HPLC have been described previously [21] .
Animals Male C57BL/6 mice (8 weeks of age) were obtained from the Experimental Animal Center, Chinese Academy of Science (Shanghai, China). Our experiments conformed to the ethical guidelines outlined in the Guide for the Care and Use of Laboratory Animals by the Laboratory Animal Center at Shanghai University of Traditional Chinese Medicine.
Hepatic fibrosis induced by CCl 4
To induce liver fibrosis, the mice were injected intraperitoneally (ip) with 10% CCl 4 /2 mL olive oil/kg body weight three times a week for 4 weeks [12] . After all mice were sacrificed, serum and liver samples were harvested. For histological analysis, tissue specimens were fixed in buffered formalin and embedded in paraffin wax. For immunofluorescence analysis, liver specimens were embedded in OCT compound. Serum and liver samples were kept frozen at -70 °C until analysis.
Experimental design
Two experimental protocols were performed. First, to evaluate the protective effect of CMCS against liver fibrosis, the mice were randomly divided into 4 groups (10 mice per group): normal control, CMCS control, model control and CMCS treatment. Second, to investigate the anti-fibrotic effect of CMCS in the absence of NK cells, the mice were randomly divided into 4 groups (10 mice per group): isotype+vehicle, isotype+CMCS, ASGM-1+vehicle and ASGM-1+CMCS. In the CMCS control, CMCS treatment, isotype+CMCS and ASGM-1+CMCS groups, the mice were treated orally with CMCS at a daily dose of 120 mg/kg of body weight [21] , which was equivalent to the dosage of a 60 kg adult. In the normal control, model control, isotype+vehicle and ASGM-1+vehicle groups, the mice received deionized water.
Depletion of NK cells by ASGM-1 antibody
To chronically deplete NK cells (NK1.1 + CD3 -) in vivo, the fibrotic mice were injected ip with 20 μL an anti-asialo GM-1 (ASGM-1) antibody (WAKO Pure Chemical Industries, Osaka, Japan) 8 h prior to treatment with CMCS. Because NK cell activity has been reported to be markedly reduced on day 3 after one injection, begins to recover on day 7 and rises to more than 50% of the original value on d 14 [23] , in the present study, the ASGM-1 injection was performed on days 0, 3, 7, 14 and 21. Simultaneously, the same lot of rabbit IgG (WAKO Pure Chemical Industries) was used as an isotype control for the ip injection. No mortality was observed in the mice that were treated with the isotype control or ASGM-1+CMCS, while three mice in the ASGM-1+vehicle group died on day 24.
Measurement of serum indicators of liver function and hydroxyproline (Hyp) content The activities of serum ALT, aspartate aminotransferase (AST), Peng Y et al Acta Pharmacologica Sinica npg total bilirubin (T.Bil) and albumin (Alb) were quantitated using commercial kits according to the instructions provided by the manufacturer (Nanjing JianCheng Bioengineering Institute, Nanjing, China), including the use of standardization. Hyp levels in tissues were measured using the method described by Jamall et al [24] .
Histopathological assessment of liver injury After routine processing, 4-μm-thick liver sections were stained with hematoxylin and eosin (H&E) for histological analysis or Sirius red staining for collagen deposition. The images were analyzed using a light microscope (Olympus BX40, Japan).
Quantitation of fibrosis
Quantitation of fibrosis was performed as described previously [25] . Briefly, the relative area of the area of fibrosis was expressed as a % of the total liver area, which was analyzed based on 35 visual fields of 7 Sirius red-stained liver sections per mouse. Each field was observed at 10× magnification using a light microscope (Olympus BX40), and then Alliance software was used for the data analysis. To evaluate the relative area of fibrosis, the measured collagen area was divided by the net field area and then multiplied by 100. Subtraction of the vascular luminal area from the total field area yielded the final calculation of the net fibrosis area.
Simultaneous staining of liver tissue with desmin antibody and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) Fresh liver tissues were embedded in OCT compound (SAKURA, CA, USA) and stored at -70 °C. The frozen tissue block was sectioned using a cryotome (Leica CM1850, Germany). Ten-micrometer-thick cryostat sections were cut, transferred to poly-L-lysine-coated slides and fixed in 4% formaldehyde (Dingguo, Shanghai, China). To identify HSCs, the sections were stained with a rabbit anti-desmin antibody (Abcam, CA, USA) as the primary antibody and then incubated with FITC-conjugated Affinipure Donkey Anti-Rabbit IgG (H+L) (Proteintech, USA) secondary antibody. Apoptosis was detected using a one-step TUNEL kit (Beyotime, Haimen, China) according to the manufacturer's protocol. The tissues were finally stained with 4',6-diamidino-2-phenylindole (DAPI) to visualize the nuclei. Images were obtained using a confocal microscope (Fluoview FV10i, Olympus, Japan) equipped with the ultraviolet/visible light LD laser combination. Photographs were obtained with Olympus confocal software.
Isolation of liver mononuclear cells
Mouse livers were removed and pressed through 200-gauge stainless steel mesh. The liver cell suspension was collected and suspended in 0.2% BSA-PBS, a solution containing phosphate-buffered saline (PBS) and 0.2% bovine serum albumin (BSA). The parenchymal cells (pellet) were separated from the mononuclear cells (MNCs) (supernatant) by centrifugation at 650 r/min for 1 min. The supernatant containing MNCs was collected, transferred into a new tube, washed twice in 0.2% BSA-PBS and centrifuged at 1500 r/min for 5 min. The supernatant was aspirated completely, and the cell pellet was resuspended in 40% Percoll (GE Healthcare, Sweden). The Percoll (70%) was gently added from the bottom of the cell suspension and centrifuged for 20 min at 2000 r/min. The cells from the layer between the 40%-70% gradient interface were collected, washed twice in 0.2% BSA-PBS and resuspended in 0.2% BSA-PBS to count the cell numbers using the Trypan blue stain (Gibco, USA).
Flow cytometric analysis
Liver MNCs were adjusted to a concentration of 2×10 7 cells/ mL in 0.2% BSA-PBS. A volume of 50 µL cell suspension was incubated with an anti-mouse CD16/CD32 antibody (eBioscience, San Diego, CA, USA) to block the FcR on ice for 15 min and washed with 0.2% BSA-PBS. The proportions of NK1.1 + CD3 -and NK1.1 + CD3 -NKG2D + cells were determined using anti-NKG2D, anti-NK1.1 and anti-CD3 antibodies (BD PharMingen, San Diego, CA, USA). Flow cytometric analysis was performed using a FACSArray bioanalyzer (BD Bioscience, CA, USA).
Tissue RNA extraction, reverse transcription and real-time fluorescence quantitative PCR (RT-qPCR) Total RNA was extracted from the frozen liver tissue using TRIzol reagent (Sangon Biotech, Shanghai, China). RNA was then used as a template for reverse transcription into singlestranded cDNA with random primers and reagents supplied in the Reverse Transcription Reagent Kit with gDNA Eraser, according to the manufacturer's protocol (TaKaRa, Dalian, China). The synthesized β-actin gene was amplified as an internal control, and the other primers used are listed in Table   Table 1 . Real-time quantitative PCR primers used in this study. 
Statistical analysis
All data were analyzed using PASW Statistics 18 software. Differences between groups were assessed by nonparametric one-way analysis of variance (ANOVA) followed by the least significant difference (LSD) post hoc test. Values in the text are means±standard deviation (SD). P<0.05 was considered statistically significant.
Results
CMCS alleviates CCl 4 -induced liver fibrosis in mice
The effect of CMCS on liver fibrosis was observed ( Figure 1A ). As shown in Figure 1B , C, D & E, serum liver functions were significantly improved in CMCS-treated mice in comparison to the model control (P<0.01). Fewer vacuolated cells and less mononuclear cell infiltration were observed in the portal area, and hepatocellular degeneration was significantly decreased after CMCS treatment ( Figure 1F ). Furthermore, in the model control, the hepatic parenchyma was expanded by collagen fibers, and lobules were separated by fibrous septa surrounding the hepatocytes. Liver fibrosis was efficiently alleviated after CMCS treatment ( Figure 1G ). Both the extent of hepatic fibrosis and the ratio of the positive area of collagen deposition were significantly reduced in CMCS-treated mice compared with the model control ( Figure 1H, I ). In addition, hepatic Hyp content was decreased in response to CMCS treatment in the model mice ( Figure 1J ).
CMCS promotes hepatic NK cell activation in CCl 4 -induced liver fibrosis in mice Next, we examined the effects of CMCS on the activities of liver NK cells in CCl 4 -induced liver fibrosis. As shown in Figure 2A and C, the frequency of liver NK cells (NK1.1 + CD3 -) was significantly decreased after CCl 4 treatment, whereas the frequency of liver NK cells in the CMCS treatment group was significantly elevated. The expression of NKG2D, which is a C-type lectin-like activation receptor on the surface of NK cells, was also assayed. With the decreasing trend in the frequency of liver NK cells after CCl 4 injection, the expression of NKG2D was diminished accordingly in the model control group while they were up-regulated in the CMCS treatment group (Figure 2B, D) , suggesting that CMCS treatment could strengthen the activity of hepatic NK cells in CCl 4 -induced liver fibrosis. Because NK cells have been shown to exert antifibrotic activity on activated HSCs by the upregulation of the NKG2D ligand RAE-1 [12] , we assumed that CMCS could promote NK cell activity by elevating the levels of RAE-1 on HSCs. To test this hypothesis, the expression levels of RAE-1ε and RAE-1δ mRNA were assessed. As expected, both RAE-1ε and RAE-1δ, which are ligands of NKG2D on the surface of HSCs, were upregulated in response to CMCS treatment, whereas they declined sharply in the model control group (Figure 2E, F) . Subsequently, lower expression levels of desmin and greater numbers of TUNEL-positive cells were found in the CMCS treatment group compared with the model control group (Figure 3A-C) . The mRNA expression levels of α-SMA and TGF-β were significantly decreased in CMCStreated mice ( Figure 3D, E) . These results revealed that CMCS could ameliorate CCl 4 -induced liver fibrosis by promoting the activation of hepatic NK cells against HSCs in mice.
CMCS inhibits the depletion of hepatic NK cells in CCl 4 -induced liver fibrosis in mice ASGM-1 is a rabbit polyclonal antibody that reacts with a neutral glycosphingolipid that is expressed on the surface of numerous hematopoietic cells, including NK, NKT, CD8 + T, γδT, and some CD4 + T cells, macrophages, eosinophils and basophils [26] [27] [28] [29] [30] . Nevertheless, ASGM-1 only effectively eliminates NK cells and basophils in vivo [27, 31] . Other methods, such as the application of anti-NK1.1 and anti-CD122 antibodies, are not ideal for the depletion of NK cells. The NK1.1 antibody is expressed on both NK cells (NK1.1 + CD3 -) and NKT cells (NK1.1 + CD3 + ). Therefore, anti-NK1.1 also depletes NKT cells. CD122 is expressed on CD8+T lymphocytes, NK cells, NKT cells, dendritic epidermal T cells, subsets of intraepithelial lymphocytes, and macrophages. Thus, the anti-CD122 antibody might deplete NK cells and other lymphocytes simultaneously. Furthermore, genetically modified mice with NK cell deficiencies, such as Beige and Stat5(f/f) Ncr1-iCreTg mice, are available. Unfortunately, neither of these models is ideal for assessing the role of NK cells. While Beige mice completely lack NK cells, they are also deficient in cytotoxic T cells and have impaired neutrophil activity. In contrast, while NK cell depletion in Stat5(f/f) Ncr1-iCreTg mice is selective, it is not complete, demonstrating residual NK cell numbers that are comparable to WT mice treated with ASGM-1 [32, 33] . Therefore, ASGM-1 is one of the most precise tools available to specifically eliminate NK cells in vivo.
In the present study, we used an anti-ASGM-1 antibody to deplete NK cells to investigate the effects of CMCS on liver fibrosis under the condition of NK cell depletion ( Figure 4A ). As expected, the depletion of NK cells led to severe serum liver function and aggravated fibrosis progressioin in ASGM1+vehicle group ( Figure 4F-I) , though serum liver function and Hyp remained no significance with Isotype+vehicle group (Figure 4B-E) . After CMCS treatment, liver inflammation was relieved, and collagen deposition in the liver tissue decreased ( Figure 4F, G) . Similarly, the hepatic Hyp content was reduced in response to CMCS treatment in the model mice ( Figure 4J) . Simultaneously, the frequency of hepatic NK cells was significantly increased despite NK depletion by injection of the anti-ASGM-1 antibody ( Figure 5A, C) . The expression of NKG2D on NK cells remained nearly equivalent to that in the vehicle group after CMCS treatment ( Figure 5B,  D) . The mRNA expression levels of RAE-1ε and RAE-1δ were elevated after CMCS treatment compared with the vehicle group ( Figure 5E, F) . Furthermore, greater TUNEL staining was observed around areas with reduced desmin expression after CMCS treatment (Figure 6A-C) . The mRNA expres- Figure 6D , E). Therefore, our results indicated that liver fibrosis could be improved and NK depletion could be partly inhibited by CMCS treatment.
Discussion
Chronic hepatic diseases, such as liver cirrhosis, hepatocellular carcinoma, viral hepatitis and autoimmune liver diseases, affect billions of people worldwide. These diseases are commonly associated with liver fibrosis initially. The liver, as the principal detoxifying organ in the human body, removes various pathogens, toxic chemicals and antigens from the blood, as well as metabolic waste from the circulatory system. When the liver is exposed to different types of injury, the pathological by-products lead to apoptosis or necrosis of hepatocytes. In these pathophysiological conditions, hepatic resident immune cells are recruited and infiltrate the affected areas of the organ. However, when the balance shifts toward injury, chronic inflammation of the liver occurs, which can aggravate the liver fibrosis.
As the largest immune organ in the body, the liver is enriched with different types of immunocytes, including T lymphocytes, B lymphocytes, Kupffer cells, NK cells and natural killer T cells. Among these immune cells, the liver lymphocyte population consists of large numbers of NK cells, which play a crucial role in host defense against viral infection and tumor transformation. Additionally, the functions of NK cells have garnered much attention because they have been found to be markedly altered in various liver diseases, especially in the inhibition of liver fibrosis by killing early activated HSCs [34] . Although various anti-fibrotic drugs, therapies and advanced diagnostic equipment are currently used, there remain side effects associated with anti-fibrotic treatment and challenges related to the diagnosis of asymptomatic patients. The development of a suitable medication remains a major barrier. Chinese herbal medicines have been widely used in China from the earliest times to the present day, and their medicinal value is strongly supported by clinical applications [35] . One of these herbal medicines, CMCS, is generally known for its tonic properties. It is widely used to treat conditions such as chronic liver diseases, lupus nephritis and autoimmune thyroid disease in the clinic. In our previous study, CMCS displayed beneficial effects in attenuating liver injury [21] . However, little is known about the immunological mechanism by which CMCS protects against hepatic fibrosis. Therefore, the aim of the present study was to investigate the effects of CMCS on the functions of liver NK cells during liver fibrosis.
First, we found that CMCS treatment significantly alleviated CCl4-induced high serum aminotransferase levels and reduced liver inflammation and fibrosis by suppressing the expression of α-SMA and TGF-β in liver tissue. Remarkably, the function of NK cells has been shown to be weakened in patients with chronic liver disease, including primary biliary cirrhosis and hepatitis C virus [36] . Collectively, our results provide novel insight regarding the mechanism by which CMCS impacts liver fibrosis. In addition, effective CMCS therapy in CCl 4 -induced liver fibrosis correlated with increased hepatic NK cell activity. The results also demonstrated that the antifibrotic effects of CMCS were manifested through the elevated frequency of hepatic NK cells because NKG2D, the activation receptor of NK cells, appeared to be upregulated in response to CMCS treatment.
Because hepatic NK cells were drastically reduced in the liver fibrosis model and could be significantly increased by CMCS treatment, we questioned whether CMCS could affect the depletion of NK cells during liver fibrosis. Moreover, we wondered whether the depletion of NK cells would lead to a diminished anti-fibrotic therapeutic effect of CMCS. To decipher the contribution of CMCS to the activation of liver NK cells, we opted to systemically deplete NK cells over the course of liver fibrosis development using the ASGM-1 antibody, which was injected at different times during the CCl 4 -induced liver fibrotic phase.
Simultaneously, CMCS was administered orally with the daily dosage. Liver inflammation and fibrosis were aggravated, and the frequency of hepatic NK cells was greatly decreased in response to the ASGM-1 antibody in the model mice. By contrast, after continuous administration of CMCS for 4 weeks, the rate of liver fibrosis development decelerated, and the frequency of hepatic NK cells was mildly upregulated. Although NKG2D was not augmented, the number of NK cells increased significantly following CMCS treatment. This result implied that CMCS could protect the impaired NK cells, and the ASGM-1-induced depletion of NK cells in the fibrosis model could be competitively restrained by raising the frequency of hepatic NK cells. Furthermore, when NK cells were depleted, HSCs were still inhibited because the expression levels of α-SMA and TGF-β were decreased by CMCS in a manner similar to those in the ASGM-1 vehicle group. The activation of HSCs is a key step in the development of liver fibrosis. Desmin, an intermediate filament that is typical of contractile cells, has been widely used as the "gold standard" to identify all stages of HSCs in rodent livers [37] . In the present study, we discovered a greater number of TUNEL-positive cells adjacent to the desmin-stained cells in the ASGM-1 plus CMCS group compared with the ASGM-1 vehicle group, suggesting that CMCS treatment induced the apoptosis of activated HSCs. Taken together, these results demonstrated that CMCS was also effective in relieving CCl 4 -induced liver fibrosis and promoting NK cell activation in the background of ASGM-1-induced NK cell depletion.
Conclusion
CMCS was effective for alleviating liver fibrosis induced by CCl 4 by promoting the activity of hepatic NK cells. Furthermore, CMCS could improve liver fibrosis by partially inhibiting the inactivation of NK cells by ASGM-1.
